Yayınlar & Eserler

Yayın Ağı
Makaleler 14
Tümü (14)
SCI-E, SSCI, AHCI (10)
SCI-E, SSCI, AHCI, ESCI (11)
ESCI (1)
Scopus (13)
TRDizin (4)

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.
Acta Medica , cilt.56, sa.3, ss.186-198, 2025 (TRDizin) Creative Commons License identifier

2. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

3. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial

YILMAZ F., YAŞAR S., Mandel N. M., Kacan T., Ozdemir M., DOĞU G. G., et al.
TARGETED ONCOLOGY , cilt.19, ss.957-964, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

4. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., et al.
CANCERS , cilt.16, sa.12, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

5. Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study

Yaşar S., Yilmaz F., Utkan G., Algın E., Bayram D., Tamam S., et al.
ANNALS OF SURGICAL ONCOLOGY , cilt.31, sa.6, ss.1-9, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

6. Prognostic Factors for Survival in Patients with Metastatic Colon Carcinoma

YILMAZ F., Karabulut C. C., ÖZDEMİR F., Aydin F.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.34, sa.3, ss.148-154, 2024 (SCI-Expanded, Scopus) identifier identifier

7. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

8. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.
European Archives of Oto-Rhino-Laryngology , cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

9. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

10. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin) Creative Commons License identifier identifier

11. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

12. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

13. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

14. Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?

Yilmaz F., Yasar S., Tuncali M. C., Akin S.
Seminars in oncology , cilt.48, sa.4-6, ss.279-282, 2021 (SCI-Expanded, Scopus) identifier
Metrikler

Yayın

14

Yayın (WoS)

11

Yayın (Scopus)

13

Atıf (WoS)

23

H-İndeks (WoS)

1

Atıf (Scopus)

18

H-İndeks (Scopus)

2

Açık Erişim

5
BM Sürdürülebilir Kalkınma Amaçları